Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Effect of lycopene supplementation on insulin-like growth factor-1 and insulin-like growth factor binding protein-3: a double-blind, placebo-controlled trial

European Journal of Clinical Nutrition volume 61, pages 1196–1200 (2007)Cite this article

Abstract

Objective:

Studies have suggested a link between lycopene and insulin-like growth factor-1 (IGF-1). The aim of this study was to test the effect of lycopene supplementation on IGF-1 and binding protein-3 (IGFBP-3) status in healthy male volunteers.

Design, setting, subjects and intervention:

This was a 4 week randomized, double-blind, placebo-controlled study of lycopene supplementation (15 mg/day) in healthy male volunteers (n=20). Fasting blood samples were collected at baseline and after 4 weeks. Samples were analysed for lycopene by high-performance liquid chromatography (HPLC) and IGF-1 and IGFBP-3 by enzyme-linked immunosorbent assay (ELISA). Changes in end points from baseline were compared in those who received placebo versus those who received the lycopene supplement.

Results:

Median change in lycopene from baseline (post-supplement – baseline) was higher in subjects in the intervention than those on placebo (lycopene group 0.29 (0.09, 0.46); placebo group 0.03 (−0.11, 0.08) μmol/l; median (25th, 75th percentiles), P<0.01). There was no difference in median change in IGF-1 concentrations (lycopene group –0.6 (−2.6, 1.9); placebo group –1.15 (−2.88, 0.95) nmol/l, P=0.52), or median change in IGFBP-3 concentrations (lycopene group 245 (−109, 484); placebo group 101 (−34, 234) nmol/l, P=0.55) between intervention and control groups. Change in lycopene concentration was associated with the change in IGFBP-3 in the intervention group (r=0.78; P=0.008; n=10).

Conclusions:

Lycopene supplementation in healthy male subjects has no effect on IGF-1 or IGFBP-3 concentrations in a healthy male population. However, the association between change in lycopene concentration and change in IGFBP-3 in the intervention group suggests a potential effect of lycopene supplementation on IGFBP-3.

Sponsorship:

University-funded.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  • Craft NE, Wise SA, Soares JH (1992). Optimisation of an isocratic high performance liquid chromatography separation of carotenoids. J Chromatogr 589, 171–176.

    Article  CAS  Google Scholar 

  • Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB et al. (2003). Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 12, 84–89.

    CAS  PubMed  Google Scholar 

  • Graydon R, Woodside JV, Young IS (2003). Lycopene supplementation has no effect on IGF-1 status in healthy male subjects. Proc Nutr Soc 62, 18A.

    Google Scholar 

  • Gunnell D, Oliver SE, Peters TJ, Donovan JL, Persad R, Maynard M et al. (2003). Are diet-prostate cancer associations mediated by the IGF axis? A cross sectional analysis of diet, IGF-1 and IGFBP-3 in healthy middle-aged men. Br J Cancer 88, 1682–1686.

    Article  CAS  Google Scholar 

  • Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et al. (1998). Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 351, 1393–1396.

    Article  CAS  Google Scholar 

  • Hoppe PP, Kramer K, van den Berg H, Steenge G, van Vliet T (2003). Synthetic and tomato-based lycopene have identical bioavailability in humans. Eur J Nutr 42, 272–278.

    Article  CAS  Google Scholar 

  • Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A et al. (2000). Lycopene interferes with cell cycle progression and IGF-1 signalling in mammary cancer cells. Nutr Cancer 36, 101–111.

    Article  CAS  Google Scholar 

  • Kucuk O, Sarkar FH, Sakr W (2001). Phase II randomised clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10, 861–868.

    CAS  PubMed  Google Scholar 

  • Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M et al. (1995). Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 24, 257–266.

    Article  CAS  Google Scholar 

  • Liu C, Lian F, Smith DE, Russell RM, Wang XD (2003). Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 63, 3138–3144.

    CAS  PubMed  Google Scholar 

  • Mucci LA, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, Spanos E et al. (2001). Are dietary influences on the risk of prostate cancer mediated through the IGF system? Br J Urol Int 87, 814–820.

    Article  CAS  Google Scholar 

  • Nahum A, Zeller L, Danilenko M, Prall OW, Watts CK, Sutherland RL et al. (2006). Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr 45, 275–282.

    Article  CAS  Google Scholar 

  • Rao AV, Agarwal S (1999). Role of lycopene as antioxidant carotenoid in the prevention of chronic diseases: a review. Nutr Res 19, 305–323.

    Article  CAS  Google Scholar 

  • Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004). Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363, 1346–1353.

    Article  CAS  Google Scholar 

  • Riso P, Brusamolino A, Martinetti A, Porrini M (2006). Effect of a tomato drink intervention on insulin-like growth factor (IGF)-1 serum levels in healthy subjects. Nutr Cancer 55, 157–162.

    Article  CAS  Google Scholar 

  • Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH et al. (2000). Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92, 1910–1917.

    Article  CAS  Google Scholar 

  • Voskuil DW, Vrieling A, van't Veer LJ, Kampman E, Rookus MA (2005). The insulin-like growth factor system in cancer prevention: potential of dietary intervention strategies. Cancer Epidemiol Biomarkers Prev 14, 195–203.

    PubMed  Google Scholar 

  • Vrieling A, Voskuil DW, Bueno de Mesquita HB, Kaaks R, van Noord PA, Keinan-Boker L et al. (2004). Dietary determinants of circulating insulin-like growth factor (IGF)-1 and IGF binding proteins 1, -2 and -3 in women in the Netherlands. Cancer Causes Control 15, 787–796.

    Article  Google Scholar 

  • Woodside JV, McCall D, McGartland C, Young IS (2005). Micronutrients: dietary intake versus supplement use. Proc Nutr Soc 64, 543–553.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The lycopene and placebo capsules were kindly supplied by BASF Aktiengesellschaft, Ludwigshafen, Germany. We thank to Mr Alistair Magill for assistance with the IGF-1 assay.

Author information

Authors and Affiliations

  1. Nutrition and Metabolism Group, Centre for Clinical and Population Science, Queen's University Belfast, Northern Ireland, Belfast, UK

    R Graydon, S E C M Gilchrist, I S Young & J V Woodside

  2. BASF Aktiengesellschaft, Ludwigshafen, Germany

    U Obermüller-Jevic & O Hasselwander

Authors
  1. R Graydon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S E C M Gilchrist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I S Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U Obermüller-Jevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Hasselwander
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J V Woodside
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J V Woodside.

Additional information

Guarantor: JV Woodside.

Contributors: RG completed the subject recruitment, laboratory analysis and drafted the manuscript, SECMG contributed to the laboratory analysis, developed the laboratory method for lycopene, and contributed to the current manuscript. ISY devised the original study design and contributed to current manuscript. UOJ and OH contributed to the study design and the current manuscript. JVW devised the original study design, carried out the statistical analyses, and contributed to the current manuscript.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Graydon, R., Gilchrist, S., Young, I. et al. Effect of lycopene supplementation on insulin-like growth factor-1 and insulin-like growth factor binding protein-3: a double-blind, placebo-controlled trial. Eur J Clin Nutr 61, 1196–1200 (2007). https://doi.org/10.1038/sj.ejcn.1602632

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ejcn.1602632

Keywords

  • lycopene
  • insulin-like growth factor-1 (IGF-1)
  • insulin-like growth factor binding protein-3 (IGFBP-3)

This article is cited by

Search

Advanced search

Quick links